Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Rachel, Butler"'
Autor:
Louise C Brown, David Fisher, Richard Adams, Jenny Seligmann, Matthew Seymour, Richard Kaplan, Susan D Richman, Philip Quirke, Rachel Butler, Helen Roberts, Janet Graham, Richard H Wilson, Timothy S Maughan
Publikováno v:
Efficacy and Mechanism Evaluation, Vol 9, Iss 9 (2022)
Background: Complex trials with innovative designs are becoming increasingly common and offer the potential to improve patient outcomes in a shorter time frame. There is evidence that patients with colorectal cancer fall into different subgroups with
Externí odkaz:
https://doaj.org/article/a710ce8c7ebb4534b2145ccccfea160e
Autor:
Ainhoa Arana Echarri, Mark Beresford, John P. Campbell, Robert H. Jones, Rachel Butler, Kenneth J. Gollob, Patricia C. Brum, Dylan Thompson, James E. Turner
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Breast cancer is the most common malignancy among women worldwide. Over the last four decades, diagnostic and therapeutic procedures have improved substantially, giving patients with localized disease a better chance of cure, and those with more adva
Externí odkaz:
https://doaj.org/article/f807173b5d584635ba80aabeca1f7f63
Autor:
Cleo Keppens, Elisabeth M. C. Dequeker, Simon J. Patton, Nicola Normanno, Francesca Fenizia, Rachel Butler, Melanie Cheetham, Jennifer A. Fairley, Hannah Williams, Jacqueline A. Hall, Ed Schuuring, Zandra C. Deans, On behalf of IQN Path ASBL
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Molecular analysis of circulating tumour DNA (ctDNA) is becoming increasingly important in clinical treatment decisions. A pilot External Quality Assessment (EQA) scheme for ctDNA analysis was organized by four European EQA provid
Externí odkaz:
https://doaj.org/article/3b377a7e3c754c35805acda84dcc799a
Autor:
Nicola E. Annels, Mehreen Arif, Guy R. Simpson, Mick Denyer, Carla Moller-Levet, David Mansfield, Rachel Butler, Darren Shafren, Gough Au, Margaret Knowles, Kevin Harrington, Richard Vile, Alan Melcher, Hardev Pandha
Publikováno v:
Molecular Therapy: Oncolytics, Vol 9, Iss , Pp 1-12 (2018)
As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhe
Externí odkaz:
https://doaj.org/article/547e325fd60c43019bb01a1537f873cb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Neal, Navani, Rachel, Butler, Salma, Ibrahimo, Anjali, Verma, Matthew, Evans, Gary J, Doherty, Samreen, Ahmed
Publikováno v:
Lung Cancer. 172:142-153
Targeted therapy against actionable variants has revolutionised the treatment landscape for non-small cell lung cancer (NSCLC). Approximately half of NSCLC adenocarcinomas have an actionable variant, making molecular testing a critical component of t
Autor:
Sacha J Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Sian Morgan, Magdalena Meissner, Catherine Bale, Pavel Bezecny, Sarah Moon, Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Elza C de Bruin, Gaia Schiavon, Andrew Foxley, Robert H Jones
Publikováno v:
Howell, S J, Casbard, A, Carucci, M, Ingarfield, K, Butler, R, Morgan, S, Meissner, M, Bale, C, Bezecny, P, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, de Bruin, E C, Schiavon, G, Foxley, A & Jones, R H 2022, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION) : overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial ', The Lancet. Oncology, vol. 23, no. 7, pp. 851-864 . https://doi.org/10.1016/S1470-2045(22)00284-4
BACKGROUND: Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The ben
Autor:
Ainhoa Arana Echarri, Lauren Struszczak, Mark Beresford, John P Campbell, Robert H Jones, Rachel Butler, Dylan Thompson, James E Turner
Publikováno v:
Cancer Research. 82:P1-04
Introduction: T cells are important for tumour control and surveillance, but it is not well known how breast cancer treatment impacts their characteristics in blood. Methods: Healthy women (n=38, age 45 ± 11 y), breast cancer survivors (n=27, age 56
Autor:
Janet Graham, Mahesh K. B. Parmar, Emma Yates, Tim Maughan, Jenny F. Seligmann, Louise Brown, David Fisher, Kai-Keen Shiu, Fiona Collinson, Ewan Brown, Philip Quirke, Stephen Falk, Richard H. Wilson, Susan D. Richman, Gary Middleton, Harpreet Wasan, Richard Kaplan, Richard Adams, Rachel Butler, Matthew T. Seymour, Leslie Samuel
Publikováno v:
Journal of Clinical Oncology. 39:3693-3704
PURPOSE Despite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without detriment to overall survival (O
Publikováno v:
Psychology in the Schools. 58:585-600